These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

772 related articles for article (PubMed ID: 9152373)

  • 21. FK419, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, ameliorates brain infarction associated with thrombotic focal cerebral ischemia in monkeys: comparison with tissue plasminogen activator.
    Maeda M; Moriguchi A; Mihara K; Aoki T; Takamatsu H; Matsuoka N; Mutoh S; Goto T
    J Cereb Blood Flow Metab; 2005 Jan; 25(1):108-18. PubMed ID: 15678117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disposition of L-738,167, a potent and long-acting fibrinogen receptor antagonist, in dogs. Dose-dependent pharmacokinetics.
    Prueksaritanont T; Gorham LM; Naue JA; Hamill TG; Askew BC; Vyas KP
    Drug Metab Dispos; 1997 Mar; 25(3):355-61. PubMed ID: 9172954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model.
    Huang J; Driscoll EM; Gonzales ML; Park AM; Lucchesi BR
    J Pharmacol Exp Ther; 2000 Nov; 295(2):492-9. PubMed ID: 11046080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monitoring platelet inhibition during chronic oral platelet glycoprotein IIb/IIIa blockade: are we missing something?
    Serebruany VL; McKenzie ME; Levin DJ; Gurbel PA
    Thromb Haemost; 2000 Feb; 83(2):356-7. PubMed ID: 10739404
    [No Abstract]   [Full Text] [Related]  

  • 25. Antithrombotic activity of SR 46349, a novel, potent and selective 5-HT2 receptor antagonist.
    Herbert JM; Bernat A; Barthelemy G; Dol F; Rinaldi M
    Thromb Haemost; 1993 Mar; 69(3):262-7. PubMed ID: 8470049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation between the in vivo efficacy of GPIIb/IIIa receptor antagonists (m7E3, MK-383 and DMP-728) and ex vivo platelet inhibition.
    Huang J; Rebello SS; Faul JD; Lucchesi BR
    Pharmacology; 1999 May; 58(5):252-64. PubMed ID: 10087466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancement by ticlopidine of the inhibitory effect on in vitro platelet aggregation of the glycoprotein IIb/IIIa inhibitor tirofiban.
    Umemura K; Kondo K; Ikeda Y; Nakashima M
    Thromb Haemost; 1997 Nov; 78(5):1381-4. PubMed ID: 9408023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of FK633, an ultra-short acting glycoprotein IIb/IIIa antagonist on platelet preservation during and after cardiopulmonary bypass.
    Tabata S; Yamaguchi S; Nagamine H; Tomita S; Arai S; Takemura H; Watanabe G
    Eur J Cardiothorac Surg; 2004 Aug; 26(2):289-93. PubMed ID: 15296885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets.
    Bednar RA; Gaul SL; Hamill TG; Egbertson MS; Shafer JA; Hartman GD; Gould RJ; Bednar B
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1317-26. PubMed ID: 9618439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased potency and decreased elimination of lamifiban, a GPIIb-IIIa antagonist, in patients with severe renal dysfunction.
    Lehne G; Nordal KP; Midtvedt K; Goggin T; Brosstad F
    Thromb Haemost; 1998 Jun; 79(6):1119-25. PubMed ID: 9657435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonpeptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217.
    Cook JJ; Holahan MA; Lyle EA; Ramjit DR; Sitko GR; Stranieri MT; Stupienski RF; Wallace AA; Hand EL; Gehret JR; Kothstein T; Drag MD; McCormick GY; Perkins JJ; Ihle NC; Duggan ME; Hartman GD; Gould RJ; Lynch JJ
    J Pharmacol Exp Ther; 1996 Jul; 278(1):62-73. PubMed ID: 8764336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Restoration of middle cerebral artery thrombosis by novel glycoprotein IIb/IIIa antagonist FK419 in guinea pig.
    Moriguchi A; Mihara K; Aoki T; Maeda M; Tojo N; Matsuoka N; Mutoh S
    Eur J Pharmacol; 2004 Sep; 498(1-3):179-88. PubMed ID: 15363993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo.
    Herault JP; Peyrou V; Savi P; Bernat A; Herbert JM
    Thromb Haemost; 1998 Feb; 79(2):383-8. PubMed ID: 9493595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model.
    Wang K; Zhou X; Huang Y; Khalil M; Wiktor D; van Giezen JJ; Penn MS
    Thromb Haemost; 2010 Sep; 104(3):609-17. PubMed ID: 20694285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New platelet fibrinogen receptor glycoprotein IIb-IIIa antagonists: orally active series of N-alkylated amidines with a 6,6-bicyclic template.
    Okumura K; Shimazaki T; Aoki Y; Yamashita H; Tanaka E; Banba S; Yazawa K; Kibayashi K; Banno H
    J Med Chem; 1998 Oct; 41(21):4036-52. PubMed ID: 9767641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
    Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
    Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of carotid artery thrombosis after oral administration of the glycoprotein IIb/IIIa antagonist CRL42796.
    Hennan JK; Willens DE; Driscoll EM; Hong TT; Giboulot T; Lucchesi BR
    J Cardiovasc Pharmacol; 2003 Jul; 42(1):71-7. PubMed ID: 12827029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb/IIIa inhibitors in animal models of platelet-mediated thrombosis.
    Collen D; Lu HR; Stassen JM; Vreys I; Yasuda T; Bunting S; Gold HK
    Thromb Haemost; 1994 Jan; 71(1):95-102. PubMed ID: 8165652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist.
    Mousa SA; Bozarth JM; Forsythe MS; Jackson SM; Leamy A; Diemer MM; Kapil RP; Knabb RM; Mayo MC; Pierce SK
    Circulation; 1994 Jan; 89(1):3-12. PubMed ID: 8281661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional relevance of the expression of ligand-induced binding sites in the response to platelet GP IIb/IIIa antagonists in vivo.
    Murphy NP; Pratico D; Fitzgerald DJ
    J Pharmacol Exp Ther; 1998 Aug; 286(2):945-51. PubMed ID: 9694954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.